Different Pigmentation Risk Loci for High-Risk Monosomy 3 and Low-Risk Disomy 3 Uveal Melanomas.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
07 02 2022
07 02 2022
Historique:
received:
04
05
2021
revised:
06
07
2021
accepted:
19
08
2021
pubmed:
24
8
2021
medline:
22
3
2022
entrez:
23
8
2021
Statut:
ppublish
Résumé
Uveal melanoma (UM), a rare malignant tumor of the eye, is predominantly observed in populations of European ancestry. UMs carrying a monosomy 3 (M3) frequently relapse mainly in the liver, whereas UMs with disomy 3 (D3) are associated with more favorable outcome. Here, we explored the UM genetic predisposition factors in a large genome-wide association study (GWAS) of 1142 European UM patients and 882 healthy controls . We combined 2 independent datasets (Global Screening Array) with the dataset described in a previously published GWAS in UM (Omni5 array), which were imputed separately and subsequently merged. Patients were stratified according to their chromosome 3 status, and identified UM risk loci were tested for differential association with M3 or D3 subgroups. All statistical tests were 2-sided. We recapitulated the previously identified risk locus on chromosome 5 on CLPTM1L (rs421284: odds ratio [OR] =1.58, 95% confidence interval [CI] = 1.35 to 1.86; P = 1.98 × 10-8) and identified 2 additional risk loci involved in eye pigmentation: IRF4 locus on chromosome 6 (rs12203592: OR = 1.76, 95% CI = 1.44 to 2.16; P = 3.55 × 10-8) and HERC2 locus on chromosome 15 (rs12913832: OR= 0.57, 95% CI = 0.48 to 0.67; P = 1.88 × 10-11). The IRF4 rs12203592 single-nucleotide polymorphism was found to be exclusively associated with risk for the D3 UM subtype (ORD3 = 2.73, 95% CI = 1.87 to 3.97; P = 1.78 × 10-7), and the HERC2 rs12913832 single-nucleotide polymorphism was exclusively associated with risk for the M3 UM subtype (ORM3 = 2.43, 95% CI = 1.79 to 3.29; P = 1.13 × 10-8). However, the CLPTM1L risk locus was equally statistically significant in both subgroups. This work identified 2 additional UM risk loci known for their role in pigmentation. Importantly, we demonstrate that UM tumor biology and metastatic potential are influenced by patients' genetic backgrounds.
Sections du résumé
BACKGROUND
Uveal melanoma (UM), a rare malignant tumor of the eye, is predominantly observed in populations of European ancestry. UMs carrying a monosomy 3 (M3) frequently relapse mainly in the liver, whereas UMs with disomy 3 (D3) are associated with more favorable outcome. Here, we explored the UM genetic predisposition factors in a large genome-wide association study (GWAS) of 1142 European UM patients and 882 healthy controls .
METHODS
We combined 2 independent datasets (Global Screening Array) with the dataset described in a previously published GWAS in UM (Omni5 array), which were imputed separately and subsequently merged. Patients were stratified according to their chromosome 3 status, and identified UM risk loci were tested for differential association with M3 or D3 subgroups. All statistical tests were 2-sided.
RESULTS
We recapitulated the previously identified risk locus on chromosome 5 on CLPTM1L (rs421284: odds ratio [OR] =1.58, 95% confidence interval [CI] = 1.35 to 1.86; P = 1.98 × 10-8) and identified 2 additional risk loci involved in eye pigmentation: IRF4 locus on chromosome 6 (rs12203592: OR = 1.76, 95% CI = 1.44 to 2.16; P = 3.55 × 10-8) and HERC2 locus on chromosome 15 (rs12913832: OR= 0.57, 95% CI = 0.48 to 0.67; P = 1.88 × 10-11). The IRF4 rs12203592 single-nucleotide polymorphism was found to be exclusively associated with risk for the D3 UM subtype (ORD3 = 2.73, 95% CI = 1.87 to 3.97; P = 1.78 × 10-7), and the HERC2 rs12913832 single-nucleotide polymorphism was exclusively associated with risk for the M3 UM subtype (ORM3 = 2.43, 95% CI = 1.79 to 3.29; P = 1.13 × 10-8). However, the CLPTM1L risk locus was equally statistically significant in both subgroups.
CONCLUSIONS
This work identified 2 additional UM risk loci known for their role in pigmentation. Importantly, we demonstrate that UM tumor biology and metastatic potential are influenced by patients' genetic backgrounds.
Identifiants
pubmed: 34424336
pii: 6356526
doi: 10.1093/jnci/djab167
pmc: PMC8826635
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
302-309Subventions
Organisme : NCI NIH HHS
ID : U01 CA155309
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press.
Références
Int J Mol Sci. 2020 Sep 28;21(19):
pubmed: 32998469
Int J Cancer. 2014 Jun 15;134(12):2961-71
pubmed: 24272143
Cell. 2013 Nov 21;155(5):1022-33
pubmed: 24267888
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Photochem Photobiol. 2006 May-Jun;82(3):733-7
pubmed: 16542109
Clin Cancer Res. 2019 Sep 15;25(18):5663-5673
pubmed: 31285370
Forensic Sci Int Genet. 2011 Jun;5(3):170-80
pubmed: 20457092
Melanoma Res. 2020 Apr;30(2):166-172
pubmed: 31626034
Cancer Res. 2014 May 15;74(10):2785-95
pubmed: 24648346
Cancer Res. 2014 Feb 15;74(4):1116-27
pubmed: 24366883
Nat Rev Genet. 2019 May;20(5):299-309
pubmed: 30760854
Nat Commun. 2020 May 15;11(1):2408
pubmed: 32415113
Nat Genet. 2013 Aug;45(8):933-6
pubmed: 23793026
Genome Res. 2012 Mar;22(3):446-55
pubmed: 22234890
Hum Mol Genet. 2015 May 1;24(9):2649-61
pubmed: 25631878
Dermatology. 2017;233(1):1-15
pubmed: 28463841
Hum Genet. 2007 Nov;122(3-4):311-26
pubmed: 17619204
Cancer Discov. 2013 Oct;3(10):1122-1129
pubmed: 23861464
Nat Commun. 2016 Feb 04;7:10615
pubmed: 26842708
Am J Hum Genet. 2010 Jul 9;87(1):6-16
pubmed: 20602913
Pigment Cell Melanoma Res. 2015 Sep;28(5):520-44
pubmed: 26176788
Ocul Oncol Pathol. 2018 Apr;4(3):145-151
pubmed: 29765944
Arch Ophthalmol. 2006 Jan;124(1):54-60
pubmed: 16401785
Ophthalmology. 2009 Feb;116(2):340-8
pubmed: 19091418
Nat Genet. 2013 Feb;45(2):133-5
pubmed: 23313955
Nat Commun. 2020 Jan 24;11(1):496
pubmed: 31980621
Br J Ophthalmol. 2014 Jun;98(6):769-74
pubmed: 24169649
Cancer Res. 2011 Mar 1;71(5):1533-9
pubmed: 21270109
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
NPJ Genom Med. 2017;2:
pubmed: 28781888
Chem Res Toxicol. 1998 Dec;11(12):1434-40
pubmed: 9860484
Sci Rep. 2016 Aug 08;6:31191
pubmed: 27499155
Hum Mol Genet. 2014 Dec 15;23(24):6616-33
pubmed: 25027329
Pigment Cell Melanoma Res. 2009 Oct;22(5):544-62
pubmed: 19619260
Am J Hum Genet. 2016 Nov 3;99(5):1190-1198
pubmed: 27745836
Int J Cancer. 2019 Mar 15;144(6):1367-1378
pubmed: 30468251
Cancer Res. 2004 Oct 15;64(20):7205-9
pubmed: 15492234
Science. 2010 Dec 3;330(6009):1410-3
pubmed: 21051595
Am J Ophthalmol. 1984 Nov;98(5):558-61
pubmed: 6496611
Invest Ophthalmol Vis Sci. 2012 Jun 05;53(7):3331-9
pubmed: 22511634